Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 3, 2007, Pages 291-296

  McConnell, Michelle S ^a,g   Bakaki, Paul ^b   Eure, Chineta ^c   Mubiru, Michael ^b   Bagenda, Danstan ^b,d   Downing, Robert ^e   Matovu, Flavia ^b   Thigpen, Michael C ^c   Greenberg, Alan E ^f   Fowler, Mary Glenn ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e CDC Uganda   (Uganda)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

^g MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

HIV transmission; Nevirapine; Perinatal HIV infection; Resistance

Indexed keywords

NEVIRAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DELIVERY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; INFECTION RATE; INFORMATION PROCESSING; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MOTHER; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SURVIVAL; SURVIVAL RATE; THERAPY EFFECT; UGANDA; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; COHORT STUDIES; DISEASE TRANSMISSION, VERTICAL; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; NEVIRAPINE; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; UGANDA;

EID: 37349068828     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31814b97e4     Document Type: Article

References (25)

1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
2. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
3. Leroy V, Sakarovitch C, Cortina-Borja M, et al. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS. 2005;19:1865-1875.
4. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
5. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217-228.
6. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005;19:309-318.
7. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother-to-child in Tanzania, South Africa, and Uganda (Petra study): a randomized, double-blind, placebo-controlled trial. Lancet. 2002;359:1178-1186.
8. World Health Organization. 2006. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access. Available at: http://www.who.int/hiv/pub/ guidelines/pmtctguidelins2006.pdf. Accessed November 7, 2006.
9. World Health Organization. 2006. What's new in the PMTCT guidelines? Available at: http://www.who.int/hiv/mediacentre/fs_2006guidelines_pmtct/en. Accessed November 7, 2006.
10. DeCock K, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283:1175-1182.
11. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 2000;14:F111-F115.
12. Chaix ML, Ekouevi DK, Peytavin G, et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother. 2007;51:896-901.
13. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951-1957.
14. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229-240.
15. Johnson JA, Li J-F, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005;192:16-23.
16. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005;192:24-29.
17. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA. 2006;103:7094-7099.
18. Loubser S, Balfe P, Sherman G, et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006;20:995-1002.
19. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-147.
20. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women exposed to single-dose nevirapine for prevention of mother-to-child HIV transmission. AIDS. 2007;21:957-964.
21. Martinson N, Ekouevi DK, Dabis F, et al. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire. J. Acquir Immune Defic Syndr. 2007;45:206-209.
22. McIntyre JA, Martinson N, Gray GE, et al. Addition of short course Combivir (CBV) to single dose Viramune (SDNVP) for the prevention of mother-to-child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and pediatric NNRTI resistant virus [abstract TuFo0204]. Presented at: Third International AIDS Society Conference; 2005; Rio de Janeiro.
23. Gray G, McIntyre J, Hopley M, et al. NNRTI-resistant mutations in HIV-1 infected infants following single dose nevirapine (Sd-NVP) are reduced by the addition of short course zidovudine and 3TC [abstract TuPe5.4P01]. Presented at: Third International AIDS Society Conference; 2005; Rio de Janeiro.
24. Chaix M-L, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis. 2006;193:482-487.
25. McIntyre J. Preventing mother-to-child transmission of HIV: successes and challenges. BJOG. 2005;112:1196-1203.